Fingerprint
Dive into the research topics of 'Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
Sonia Pernas, Miguel Martin, Peter A. Kaufman, Marta Gil-Martin, Patricia Gomez Pardo, Sara Lopez-Tarruella, Luis Manso, Eva Ciruelos, Jose Alejandro Perez-Fidalgo, Cristina Hernando, Foluso O. Ademuyiwa, Katherine Weilbaecher, Ingrid Mayer, Timothy J. Pluard, Maria Martinez Garcia, Linda Vahdat, Jose Perez-Garcia, Achim Wach, Debra Barker, Samson Fung
- Section of Medical Oncology
- Institute of Clinical and Translational Sciences (ICTS)
- Siteman Cancer Center
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
- Section of Molecular Oncology & Developmental Therapeutics
- DBBS - Molecular Cell Biology
- DBBS - Molecular Genetics and Genomics
- DBBS - Cancer Biology
- Mentorship to Enhance Development in Academia Program
Research output: Contribution to journal › Article › peer-review
115
Scopus
citations